It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Antiviral drug developer Chimerix (NASDAQ: CMRX), which recently received the regulatory go-ahead to begin human tests of a potential Ebola drug, is launching a stock offering that could pay for those clinical trials.
The Durham, NC company on Wednesday announced plans to sell $105 million in stock, part of a $150 million shelf offering. Chimerix says underwriters also would have a 30-day option to purchase up to $15.7 million in additional shares.
Chimerix disclosed on Oct. 16 that the Food and Drug Administration had cleared the company to start Phase 2 clinical trials studying its antiviral drug brincidofovir in Ebola. Chimerix plans to conduct those trials in Europe and the United States. Studies of the drug in West Africa are also being considered.
Dr. Craig Spencer, 33, is responding well to treatment, which has included brincidofovir, according to a statement released Saturday by the city's Health and Hospitals Corp. The experimental drug has been used to treat other patients in the U.S.
When it comes to Ebola drugs, we’ve heard primarily about ZMapp, Tekmira, and vaccines. How and why did this drug, brincidofovir, seem to suddenly emerge on the Ebola treatment scene?
This module enables the “Clinical Trial in a Test Tube”™ application of the MIMIC® technology. To date, this module has been used for seasonal and pandemic influenza, Ebola, Marburg, Yellow Fever, Venezuelan equine encephalitis virus, and latent tuberculosis (Mtb) as model diseases.
VaxDesign became a wholly owned subsidiary of sanofi pasteur in 2010. The MIMIC® System was primarily developed from about 2004 through early 2009 under a $40 million contract for the Rapid Vaccine Assessment Program with the Defense Advanced Research Projects Agency (DARPA). In 2006, we began to reach out to commercial customers and collaborators, as well as non-profit organizations.
Today, we have a diverse group of collaborators, including the federal government (DTRA, Army CBMS, DARPA, WRAIR, NIST); biotechnology companies; and numerous universities